JAZZ - Jazz Pharmaceuticals

-

$undefined

N/A

(N/A)

Jazz Pharmaceuticals NASDAQ:JAZZ Jazz Pharmaceuticals plc is a global biopharmaceutical company dedicated to developing and commercializing life-changing medicines that transform the lives of patients with serious diseases - often with limited or no options. Jazz Pharmaceuticals plc has a diverse portfolio of marketed medicines and novel product candidates, from early- to late-stage development, in key therapeutic areas. The company's focus is in neuroscience, including sleep and movement disorders, and in oncology, including hematologic and solid tumors. They actively explore new options for patients including novel compounds, small molecule advancements, biologics and innovative delivery technologies. Jazz is headquartered in Dublin, Ireland and has employees around the globe, serving patients in more than 90 countries.

Location: Waterloo Exchange, Waterloo Road,Dublin 4, Ireland | Website: www.jazzpharma.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

10.88B

Cash

2.618B

Avg Qtr Burn

N/A

Short % of Float

5.85%

Insider Ownership

2.88%

Institutional Own.

96.64%

Qtr Updated

09/30/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
EPIDIOLEX® (cannabidiol) Details
Epilepsy, Dravet syndrome, Tuberous sclerosis complex, Lennox-Gastaut syndrome

Approved

Quarterly sales

Zepzelca (Lurbinectedin) Details
Cancer, Small cell lung cancer

Approved

Quarterly sales

Rylaze /Enrylaze (JZP-458) Details
Acute lymphoblastic leukemia

Approved

Quarterly sales

Xywav (JZP-258) (oxybate salts) Details
EDS in Idiopathic Hypersomnia

Approved

Quarterly sales

Zanidatamab Details
HER2-expressing cancers, Cancer, Biliary Tract Cancer

PDUFA

Approval decision

Phase 3

Data readout

EPIDIOLEX® (cannabidiol) Details
Rare diseases, Neurological disorder, Rare genetic disease, Epilepsy, Seizures

Phase 3

Data readout

Zanidatamab combo w/ chemo Details
Cancer, HER2-expressing cancers, Gastroesophageal adenocarcinomas

Phase 3

Data readout

Zepzelca +Tecentriq Details
Cancer, Small cell lung cancer

Phase 3

Update

Phase 2b

Update

Phase 2

Data readout

Phase 2

Data readout

CBDV (Cannabidivarin /GWP42006) Details
Epilepsy, Autism spectrum disorders

Phase 2

Data readout

Phase 2a

Data readout

Zepzelca (Lurbinectedin) Details
Solid tumor/s, Cancer, Endometrial cancer

Phase 1/2

Data readout

Phase 1/2

Data readout

Zanidatamab combo w/ docetaxel Details
Cancer, HER2-expressing cancers

Phase 1/2

Interim update

JZP351 (CPX-351) Details
Acute myeloid leukemia, Blood cancer, Cancer

Phase 1b

Data readout

Zanidatamab Details
Cancer, Breast cancer

Phase 1

Data readout

JZP815 Details
Solid tumor/s, Cancer

Phase 1

Data readout

JZP441 (orexin-2 receptor agonist) Details
Sleeping disorder, EDS in Idiopathic Hypersomnia , Narcolepsy

Phase 1

Update

JZP898 Details
Solid tumor/s, Cancer

Phase 1

Initiation

JZP-150 (FAAH inhibitor) Details
Post-traumatic stress disorder

Failed

Discontinued

EPIDIOLEX® (cannabidiol) Details
Rare diseases, Rare genetic disease, Rett syndrome, Neurological disorder

Failed

Discontinued

Nabiximols Details
Multiple sclerosis

Failed

Discontinued